| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/14/2023 | 137.15% | Oppenheimer | → $12 | Reiterates | → Outperform |
| 09/28/2022 | 58.1% | EF Hutton | $14 → $8 | Maintains | Buy |
| 07/22/2022 | 38.34% | Cantor Fitzgerald | → $7 | Initiates Coverage On | → Overweight |
| 03/17/2022 | 176.68% | EF Hutton | $9 → $14 | Maintains | Buy |
| 03/15/2022 | 77.87% | Oppenheimer | → $9 | Initiates Coverage On | → Outperform |
| 11/30/2021 | 433.6% | B. Riley Securities | $50 → $27 | Maintains | Buy |
| 01/15/2021 | 828.85% | B. Riley Securities | → $47 | Initiates Coverage On | → Buy |
What is the target price for BioVie (BIVI)?
The latest price target for BioVie (NASDAQ: BIVI) was reported by Oppenheimer on February 14, 2023. The analyst firm set a price target for $12.00 expecting BIVI to rise to within 12 months (a possible 137.15% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BioVie (BIVI)?
The latest analyst rating for BioVie (NASDAQ: BIVI) was provided by Oppenheimer, and BioVie reiterated their outperform rating.
When is the next analyst rating going to be posted or updated for BioVie (BIVI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioVie, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioVie was filed on February 14, 2023 so you should expect the next rating to be made available sometime around February 14, 2024.
Is the Analyst Rating BioVie (BIVI) correct?
While ratings are subjective and will change, the latest BioVie (BIVI) rating was a reiterated with a price target of $0.00 to $12.00. The current price BioVie (BIVI) is trading at is $5.06, which is within the analyst's predicted range.
